

## Attended Posters – Tuesday, 8 May 2007

- P012-T ACCELERATED BONE RESORPTION PROMOTES TUMOUR GROWTH IN A MURINE MODEL OF BREAST CANCER BONE METASTASIS**  
Y. Zheng<sup>1</sup>, H. Zhou<sup>1</sup>, J. R. K. Modzelewski<sup>1</sup>, R. Kalak<sup>1</sup>, J. M. Blair<sup>1</sup>, M. J. Seibel\*<sup>1</sup>, C. R. Dunstan<sup>1</sup>  
<sup>1</sup>*Bone Research Program, ANZAC Research Institute, University of Sydney Concord RG Hospital, Sydney, Australia*
- P015-T SYSTEMIC ADMINISTRATION OF THYROID STIMULATING HORMONE (TSH) RESTORES BONE VOLUME AND STRENGTH WITHOUT AFFECTING SERUM T3 AND T4 LEVELS IN AGED OVARECTOMIZED RATS**  
R. Sendak\*<sup>1</sup>, M. Huff<sup>1</sup>, K. Culm-Merdek<sup>1</sup>, S. Schiavi<sup>1</sup>, J. M. McPherson<sup>1</sup>, P. Simic<sup>2</sup>, S. Vukicevic<sup>2</sup>, K. T. Sampath<sup>1</sup>  
<sup>1</sup>*Research and Development, Genzyme Corporation, Framingham, United States, <sup>2</sup>Department of Anatomy, Medical School, Zagreb, Croatia*
- P018-T GONADAL ANDROGENS AND PERIPHERAL AROMATIZATION AFFECT PERIOSTEAL BONE GROWTH IN MALE MICE DURING PUBERTY**  
F. Callewaert\*<sup>1</sup>, K. Venken<sup>1</sup>, J. Ophoff<sup>1</sup>, S. Boonen<sup>1</sup>, R. Bouillon<sup>1</sup>, D. Vanderschueren<sup>1</sup>  
<sup>1</sup>*Laboratory of Experimental Medicine and Endocrinology, KULeuven, Leuven, Belgium*
- P021-T SRP3 AND SRP9 POLYMORPHISMS IN THE SOST GENE ARE ASSOCIATED WITH PERIMENOPAUSAL BONE MASS AND EARLY POSTMENOPAUSAL BONE LOSS**  
N. González-Bofill\*<sup>1</sup>, L. B. Husted<sup>1</sup>, P. Vestergaard<sup>1</sup>, C. L. Tofteng<sup>2</sup>, B. Abrahamsen<sup>3</sup>, P. Eiken<sup>4</sup>, B. L. Langdahl<sup>1</sup>  
<sup>1</sup>*Department of Endocrinology, Aarhus Hospital, Aarhus, <sup>2</sup>Department of Endocrinology, Hvidovre Hospital, Hvidovre, <sup>3</sup>Department of Endocrinology, Roskilde County Hospital, Roskilde, <sup>4</sup>Department of Endocrinology, Hillerød Hospital, Hillerød, Denmark*
- P024-T VARIATION IN THE BONE MORPHOGENETIC PROTEIN 2 GENE: BODY COMPOSITION AND BONE MINERAL DENSITY IN YOUNG AND ELDERLY WOMEN**  
F. E. A. McGuigan\*<sup>1</sup>, E. Larzenius<sup>2</sup>, M. Callreus<sup>2</sup>, L. Jansson<sup>2</sup>, P. Gerdhem<sup>2</sup>, H. Luthman<sup>3</sup>, K. Åkesson<sup>2</sup>  
<sup>1</sup>*Department of Orthopedics, <sup>2</sup>Department of Orthopaedics, <sup>3</sup>Department of Medical Genetics, Lund University, Malmö, Sweden*
- P027-T ADIPONECTIN IS A PREDICTOR OF PEAK BONE MASS IN MEN**  
M. F. Nielsen\*<sup>1</sup>, B. Abrahamsen<sup>2</sup>, T. Nielsen<sup>1</sup>, M. Andersen<sup>1</sup>, C. Hagen<sup>2</sup>, K. Brixen<sup>1</sup>  
<sup>1</sup>*Dept. of Endocrinology, Odense University Hospital, Odense, <sup>2</sup>Dept. of Endocrinology, Gentofte County Hospital, Copenhagen, Denmark*
- P030-T BLOOD LEAD LEVELS, RATES OF BONE LOSS AND INCIDENT FRACTURES: THE STUDY OF OSTEOPOROTIC FRACTURES (SOF)**  
J. A. Cauley\*<sup>1</sup>, N. Khalil<sup>1</sup>, E. O. Talbott<sup>1</sup>, J. W. Wilson<sup>2</sup>, S. B. Muldoon<sup>3</sup>, L. Morrow<sup>4</sup>, M. C. Hochberg<sup>5</sup>, T. A. Hillier<sup>6</sup>, S. R. Cummings<sup>7</sup>  
<sup>1</sup>*Epidemiology, <sup>2</sup>Biostatistics, University of Pittsburgh, Pgh, <sup>3</sup>Epidemiology, University of Louisville, Louisville, KY, <sup>4</sup>Psychiatry, University of Pittsburgh, Pgh, <sup>5</sup>Medicine, University of Maryland Medical Center, Baltimore, <sup>6</sup>Medicine, Kaiser Permanente Center for Health Research, Portland, OR, <sup>7</sup>Medicine, San Francisco Coordinating Center, CPMC, San Francisco, CA, United States*
- P033-T IBANDRONATE-INDUCED REDUCTION OF BONE TURNOVER MARKER PREDICTS ANTIFRACTURE EFFICACY**  
P. D. Miller\*<sup>1</sup>, R. Blackburn<sup>2</sup>, R. Grant<sup>3</sup>, R. R. Recker<sup>4</sup>  
<sup>1</sup>*Department of Medicine, Colorado Center for Bone Research, Lakewood, United States, <sup>2</sup>Pharmaceutical Development Medical Biostatistics, Roche Products Ltd, Welwyn Garden City, United Kingdom, <sup>3</sup>Inflammatory and Bone Diseases, Hoffmann-La Roche Inc., Nutley, <sup>4</sup>Osteoporosis Research Center, Creighton University, Omaha, United States*
- P036-T STRONTIUM RANELATE DEMONSTRATES VERTEBRAL AND NON-VERTEBRAL ANTI FRACTURE EFFICACY INCLUDING HIP FRACTURES OVER 5 YEARS IN POST MENOPAUSAL OSTEOPOROTIC WOMEN**  
J. Y. Reginster\*<sup>1</sup>, K. Brixen<sup>2</sup>, C. Cormier<sup>3</sup>, J. Cannata<sup>4</sup>

<sup>1</sup>Unité d'Exploration du Métabolisme Osseux, CHU BRULL, Liège, Belgium, <sup>2</sup>Endocrinology, Odense University Hospital, Odense, Denmark, <sup>3</sup>Rheumatology A Department, Cochin Hospital Paris V University, Paris, France, <sup>4</sup>Servicio de Metabolismo Oseo y Mineral, Hospital Central de Asturias, Oviedo, Spain

**P039-T EFFICACY OF PTH (1-84) ON VERTEBRAL AND NON-VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN WITH A HIGH RISK OF VERTEBRAL FRACTURES**

C. Roux\*<sup>1</sup>, O. Illera Martín<sup>2</sup>, J. Clausen<sup>3</sup>

<sup>1</sup>CHU Cochin, Service Rhumatologie, Paris, France, <sup>2</sup>Servicio de Reumatología, Hospital Ramón y Cajal, Madrid, Spain, <sup>3</sup>International Medical Affairs, Nycomed, Roskilde, Denmark

**P043-T INDICATION OF THINNER MINERAL PLATES IN NEW BONE OF RATS TREATED WITH SRCL2**

M. H. Bünger\*<sup>1</sup>, T. P. K. Hansen<sup>1</sup>, B. M. Bibby<sup>2</sup>, F. Besenbacher<sup>1</sup>, B. L. Langdahl<sup>3</sup>, H. Oxlund<sup>4</sup>, J. S. Pedersen<sup>1</sup>, H. Birkedal<sup>1</sup>

<sup>1</sup>Interdisciplinary Nanoscience Center, <sup>2</sup>Department of Biostatistics, University of Aarhus, <sup>3</sup>Department of Endocrinology and Metabolism C, Aarhus University Hospital, <sup>4</sup>Department of Anatomy, University of Aarhus, Aarhus, Denmark

**P046-T VIABILITY OF OSTEOCYTES IN BONE AUTOGRAFTS HARVESTED FOR DENTAL IMPLANTOLOGY**

B. Guillaume<sup>1</sup>, C. Gaudin<sup>2</sup>, S. Georgeault<sup>2</sup>, R. Mallet<sup>2</sup>, M. F. Basle<sup>2</sup>, D. Chappard\*<sup>2</sup>

<sup>1</sup>Collège Français d'Implantologie, CFI, Paris, <sup>2</sup>INSERM, EMI 0335-LHEA, Faculté de Médecine, Angers, France

**P049-T PHYSICALLY COMPETENT WOMEN DECLINE IN KINETIC PARAMETERS DURING AGING**

Y. Dionyssiotis\*<sup>1</sup>, D. Economopoulos<sup>1</sup>, A. Galanos<sup>1</sup>, G. P. Lyritis<sup>1</sup>

<sup>1</sup>Laboratory Research Musculoskeletal System, University of Athens, Kifissia, Greece

**P052-T APPLICATION OF PHOSPHOPHORYN/COLLAGEN COMPOSITE TO HORIZONTAL BONE LOSS IN PERIODONTAL DEFECTS IN VIVO**

T. Fujii\*<sup>1</sup>, T. Lombardi<sup>2</sup>, P. C. Baehni<sup>3</sup>, Y. Terada<sup>1</sup>, M. Izumikawa<sup>4</sup>, T. Saito<sup>4</sup>

<sup>1</sup>Dental Science, Health Sciences University of Hokkaido, Sapporo, Japan, <sup>2</sup>Oral Histopathology, <sup>3</sup>Preventive Dentistry, Geneva University, Geneva, Switzerland, <sup>4</sup>Operative Dentistry, Health Sciences University of Hokkaido, Sapporo, Japan

**P055-T EXTRACORPOREAL SHOCK WAVE TREATMENT OF ATROPHIC NONUNIONS – AN IN VIVO STUDY USING AN ANIMAL MODEL**

J. E. H. Hausdorf\*<sup>1</sup>, T. Tischer<sup>2</sup>, M. Maier<sup>3</sup>, V. Jansson<sup>1</sup>

<sup>1</sup>Orthopaedic Department, Ludwig-Maximilians-University, <sup>2</sup>Department of Sports Injuries, Technical University, Munich, <sup>3</sup>Orthopaedic Practice, Starnberg, Germany

**P058-T MOLECULAR ANALYSIS OF OSTEOGENESIS BY HUMAN OSTEOBLASTS ON A 3D COLLAGEN-GAG SCAFFOLD**

M. B. Keogh\*<sup>1</sup>, F. J. O'Brien<sup>1</sup>, J. S. Daly<sup>1</sup>

<sup>1</sup>Anatomy, Royal College of Surgeons, Dublin, Ireland

**P061-T TEXTURE ANALYSIS OF COMPUTED TOMOGRAPHIC IMAGES IN OSTEOPOROTIC PATIENTS WITH SINUS LIFT BONE GRAFT RECONSTRUCTION**

H. Libouban\*<sup>1</sup>, B. Guillaume<sup>2</sup>, M. F. Basle<sup>1</sup>, D. Chappard<sup>3</sup>

<sup>1</sup>INSERM, EMI 0335, Faculty of Medicine, Angers, <sup>2</sup>College Francais d'Implantologie, CFI, <sup>3</sup>INSERM, EMI 0335, Faculty of Medicine, Paris, France

**P064-T CHONDROGENIC DIFFERENTIATION OF HUMAN ADIPOSE-DERIVED MESENCHYMAL STEM CELLS**

C. Merceron\*<sup>1</sup>, C. Vinatier<sup>1</sup>, M. Masson<sup>1</sup>, L. Guigand<sup>2</sup>, J. Amiaud<sup>2</sup>, Y. Cherel<sup>2</sup>, M. Poupon<sup>3</sup>, P. Weiss<sup>1</sup>, J. Guicheux<sup>1</sup>

<sup>1</sup>UFR Odontologie, INSERM U791, LIOAD, <sup>2</sup>National Veterinary School, INRA UMR 703, <sup>3</sup>Plastic Surgery, University Hospital, Nantes, France

**P067-T DISSOLUTION PRODUCTS FROM BIOMATERIALS USED FOR BONE REGENERATION**

A. Sahlin-Platt\*<sup>1</sup>, z. Mladenovic<sup>2</sup>, M. Ransjö<sup>1</sup>

<sup>1</sup>Odontology, Oral Cell Biology, <sup>2</sup>Odontology, Oral Cell Biology, Umeå, Sweden

- P070-T SCAFFOLD GEOMETRY REGULATES TISSUE GROWTH IN VITRO**  
M. Rumpfer\*<sup>1</sup>, A. Woesz<sup>1</sup>, P. Fratzl<sup>1</sup>  
<sup>1</sup>*Department of Biomaterials, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany*
- P073-T ARTERY WALL AS A SOURCE OF OSTEOGENIC CELLS AND ITS APPLICATION FOR GUIDED BONE REGENERATION**  
M. A. Suárez-Suárez\*<sup>1</sup>, F. Ferrero-Manzanal<sup>1</sup>, A. Meana-Infiesta<sup>2</sup>, V. García<sup>2</sup>, E. García<sup>2</sup>, M. A. delBrio-León<sup>3</sup>, P. Menéndez-Rodríguez<sup>4</sup>, A. Astudillo-González<sup>4</sup>, P. Riera-Rovira<sup>3</sup>, A. Murcia-Mazón<sup>1</sup>  
<sup>1</sup>*Orthopaedic Surgery Department, Hospital Cabueñes, Gijón, <sup>2</sup>Tissue Bank, Centro Comunitario Sangre y Tejidos Asturias, <sup>3</sup>Morphology and Cellular Biology Department, Oviedo University, <sup>4</sup>Pathology Department, Hospital Central Asturias, Oviedo, Spain*
- P076-T PRENATAL PROGRAMMING OF SKELETAL DEVELOPMENT IN THE OFFSPRING: EFFECTS OF MATERNAL TREATMENT WITH 3-HYDROXY-3-METHYLBUTYRATE (HMB) ON FEMUR PROPERTIES IN GROWN PIGS**  
M. R. Tataru\*<sup>1</sup>, E. Sliwa<sup>1</sup>, W. Krupski<sup>2</sup>, T. Studzinski<sup>1</sup>  
<sup>1</sup>*Department of Animal Physiology, The Agricultural University of Lublin, <sup>2</sup>II Department of Radiology, Medical University of Lublin, Lublin, Poland*
- P079-T THE EFFICACY OF TERIPARATIDE (TPTD) IN THE RECOVERY OF DIAPHYSIAL MIDDLE PSEUDO-ARTHRITIS OF FEMOUR IN PATIENT AFFECTED BY NON RESPONDER SEVERE OSTEOPOROSIS (OPM)**  
L. Ventura\*<sup>1</sup>, A. Nardi<sup>2</sup>, I. Renzi Brivio<sup>3</sup>  
<sup>1</sup>*Internal Medicine, Azienda Ospedaliera Carlo Poma, Mantova, <sup>2</sup>SOS Dpt Patologia Osteoarticolare, Azienda ULSS 18, Rovigo, <sup>3</sup>SOC Ortopedia e Traumatologia, Azienda Ospedaliera Carlo Poma, Mantova, Italy*
- P082-T APPLIED BIOMECHANICS IN MOTORIC THERAPY FOR OSTEOPOROTIC PATIENTS**  
J. Wendlova\*<sup>1</sup>  
<sup>1</sup>*University Hospital and Policlinic, Osteological Unit, Bratislava, Slovakia*
- P087-T INFLUENCE OF CANCER CELLS ON BONE MICROENVIRONMENT IN RAT METASTASIS MODELS**  
S. Blouin<sup>1</sup>, M. F. Baslé<sup>1</sup>, D. Chappard\*<sup>1</sup>  
<sup>1</sup>*INSERM, EMI 0335, Faculté de Médecine, Angers, France*
- P090-T BIPHASIC CHANGES IN SUBCHONDRAL BONE PLATE THICKNESS IN OSTEOARTHRITIS: AN IN VIVO MICRO-COMPUTED TOMOGRAPHY STUDY**  
S. M. Botter\*<sup>1</sup>, Y. H. Sniekers<sup>1</sup>, G. J. V. van Osch<sup>2</sup>, J. H. Waarsing<sup>2</sup>, J. A. N. Verhaar<sup>2</sup>, H. A. P. Pols<sup>1</sup>, H. Weinans<sup>2</sup>, J. P. T. van Leeuwen<sup>1</sup>  
<sup>1</sup>*Internal Medicine, <sup>2</sup>Orthopedics, Erasmus Medical Centre, Rotterdam, Netherlands*
- P093-T BONE QUALITY AND HISTOMORPHOMETRY IN 7 PATIENTS WITH FLUOROSIS**  
C. Gaudin<sup>1</sup>, E. Legrand<sup>1</sup>, M. Audran<sup>1</sup>, M. F. Baslé<sup>1</sup>, D. Chappard\*<sup>2</sup>  
<sup>1</sup>*INSERM, EMI 0335-LHEA, Faculté de Médecine, <sup>2</sup>INSERM, EMI 0335-LHEA, Faculté, ANGERS, France*
- P096-T ARE OSTEOBLASTS INVOLVED IN HUMAN AUTOSOMAL RECESSIVE OSTEOPELOSIS?**  
A. Del Fattore\*<sup>1</sup>, A. Teti<sup>1</sup>  
<sup>1</sup>*Experimental Medicine, University of L'Aquila, L'Aquila, Italy*
- P099-T TUMOUR-INDUCED HYPOPHOSPHATAEMIC OSTEOMALACIA**  
B. Harbeck\*<sup>1</sup>, H. Schöcklmann<sup>2</sup>, A. Seekamp<sup>3</sup>, N. Czech<sup>4</sup>, H. Mönig<sup>5</sup>  
<sup>1</sup>*Internal Medicine, UKSH-Campus Kiel, Kiel, Germany, <sup>2</sup>Nephrology, <sup>3</sup>Traumatology, <sup>4</sup>Nuclear Medicine, <sup>5</sup>Internal Medicine, UKSH-Campus Kiel, Kiel*
- P102-T EXTRACELLULAR CALCIUM MODULATES IBANDRONATE-INDUCED GROWTH INHIBITION OF BREAST CANCER CELLS**  
F. Journe\*<sup>1</sup>, N. Kheddoumi<sup>1</sup>, C. Chaboteaux<sup>1</sup>, G. Laurent<sup>2</sup>, J. Body<sup>1</sup>  
<sup>1</sup>*Department of Internal Medicine, Institut Bordet, Brussels, <sup>2</sup>Laboratory of Histology, Université de Mons-Hainaut, Mons, Belgium*
- P105-T RESVERATROL ANALOGS AS POTENTIAL TREATMENT OF MULTIPLE MYELOMA AND BONE RELATED DISEASE. EFFECT ON MYELOMA CELLS, OSTEOCLASTS AND OSTEOBLASTS IN VITRO**

K. Kupisiewicz\*<sup>1</sup>, P. Boissy<sup>1</sup>, K. S e<sup>1</sup>, B. Abdallah<sup>2</sup>, M. Kassem<sup>2</sup>, T. Plesner<sup>3</sup>, J. Delaisse<sup>1</sup>  
<sup>1</sup>Department of Clinical Cell Biology, Vejle Hospital, Vejle, <sup>2</sup>Laboratory of Endocrinology and Metabolism, University Hospital, Odense, <sup>3</sup>Division of Hematology, Vejle Hospital, Vejle, Denmark

**P108-T EXPRESSION OF BONE MORPHOGENETIC PROTEIN-2 AND-7 DURING EXPERIMENTAL INFLAMMATORY BOWEL DISEASE**

I. Maric\*<sup>1</sup>, O. Cvijanovic<sup>1</sup>, T. Turk<sup>2</sup>, Z. Crncevic-Orlic<sup>2</sup>, D. Bobinac<sup>1</sup>  
<sup>1</sup>Department of Anatomy, School of Medicine, University of Rijeka, <sup>2</sup>Department of Internal Medicine, Clinical Hospital Rijeka, Rijeka, Croatia

**P111-T MOUSE OSTEOSARCOMA CELLS PRODUCE INSULIN-LIKE GROWTH FACTORS THAT INDUCE PRE-OSTEOBLAST CELL PROLIFERATION; INTERACTION BETWEEN BONE CELLS AND OSTEOSARCOMA CELLS**

K. Mori\*<sup>1</sup>, D. Heymann<sup>1</sup>, F. Blanchard<sup>1</sup>, F. Redini<sup>1</sup>  
<sup>1</sup>EA 3822-INSERM ERI 7 Physiopathologie de la R sorption Osseuse et Th rapie des Tumeurs Osseuses Prim, Facult  de M decine, Nantes, France

**P114-T CLINICAL BENEFITS OF MIGLUSTAT ON BONE DISEASE IN ADULT TYPE 1 GAUCHER DISEASE (GD1): A META-ANALYSIS**

G. M. Pastores\*<sup>1</sup>, D. Elstein<sup>2</sup>, M. Hrebicek<sup>3</sup>, A. Zimran<sup>2</sup>  
<sup>1</sup>Department of Neurology and Pediatrics, NYU School of Medicine, New York, United States, <sup>2</sup>Department of Medicine, Shaare Zedek Medical Centre, Jerusalem, Israel, <sup>3</sup> Institute of IMD, Prague, Czech Republic

**P117-T A HIGH THROUGHPUT METHOD OF MEASURING BONE ARCHITECTURAL DISTURBANCE IN A MURINE CIA MODEL BY MICRO-CT MORPHOMETRY**

L. Oste<sup>1</sup>, P. L. Salmon\*<sup>2</sup>, L. Van Rompuay<sup>1</sup>, G. Dixon<sup>1</sup>  
<sup>1</sup>R&D, Galapagos Ltd., Mechelen, <sup>2</sup>Application Research, Skyscan N.V., Kontich, Belgium

**P120-T FEMORAL HEAD OSTEOARTHRITIS – ANALYSIS OF BONE STRUCTURE AND TURNOVER**

M. Staresinic\*<sup>1</sup>, V. Kusec<sup>2</sup>, B. Sebecic<sup>1</sup>, D. Krpan<sup>3</sup>  
<sup>1</sup>Dept of Surgery, Clinical Hospital Merkur, <sup>2</sup>Clin Inst Lab Diagnosis, Clinical Hospital Centre Zagreb, <sup>3</sup>Dept of Internal Medicine, General Hospital Sv Duh, Zagreb, Croatia

**P123-T IMPROVE BONE METASTASIS IMAGING AND THERAPY**

K. F. Vartanyan\*<sup>1</sup>  
<sup>1</sup>Radiology, Russian Academy for Advanced Medical Studies, Moscow, Russian Federation

**P126-T EVALUATION OF A NEW TWO SITE-ELISA FOR SERUM DKK-1 IN PATIENTS WITH BREAST CANCER AND BONE METASTASES**

N. Voorzanger-Rousselot\*<sup>1</sup>, F. Journe<sup>2</sup>, S. Maitzen<sup>3</sup>, G. Hawa<sup>3</sup>, A. Lukas<sup>4</sup>, J. Body<sup>2</sup>, P. Garnero<sup>1</sup>  
<sup>1</sup>Recherche et Developement, SYNARC, LYON, France, <sup>2</sup>Dept of Internal Medicine, Inst J. Bordet, Brussels, Belgium, <sup>3</sup>Head of Research & Development, Biomedica Gruppe, <sup>4</sup>Applications, Emergentec Biodevelopment, Vienna, Austria

**P129-T VISCOELASTICITY AND FORCE TRACTION OF BONE CELLS IN 3-DIMENSIONAL MORPHOLOGY**

R. G. Bacabac\*<sup>1</sup>, D. Mizuno<sup>2</sup>, C. F. Schmidt<sup>2</sup>, F. C. MacKintosh<sup>3</sup>, T. H. Smit<sup>4</sup>, J. J. W. A. van Loon<sup>1</sup>, J. Klein-Nulend<sup>1</sup>  
<sup>1</sup>Oral Cell Biology, ACTA-Vrije Universiteit, Amsterdam, Netherlands, <sup>2</sup>Third Physical Institute, University of Göttingen, Göttingen, Germany, <sup>3</sup>Physics, Vrije Universiteit, <sup>4</sup>Physics and Medical Technology, VU University Medical Center, Amsterdam, Netherlands

**P132-T STRONTIUM RANELATE EFFECTS IN HUMAN OSTEOBLASTS SUPPORT ITS UNCOUPLING EFFECT ON BONE FORMATION AND BONE RESORPTION**

T. C. Brennan\*<sup>1</sup>, M. S. Rybchyn<sup>1</sup>, P. Halbout<sup>2</sup>, A. D. Conigrave<sup>3</sup>, R. S. Mason<sup>1</sup>  
<sup>1</sup>School of Medical Sciences, Physiology and Bosch Institute, University of Sydney, Sydney, Australia, <sup>2</sup>Therapeutic Division of Rheumatology, Institut de Recherches Internationales Servier, Courbevoie, France, <sup>3</sup>School of Molecular and Microbial Biosciences, University of Sydney, Sydney, Australia

**P135-T GENE MICROARRAY ANALYSIS IN MOUSE OSTEOBLASTS REVEALS SETS OF RELEVANT MRNAS REGULATED UNDER MODELED MICROGRAVITY**

M. Capulli\*<sup>1</sup>, A. Rufo<sup>1</sup>, A. Teti<sup>1</sup>, N. Rucci<sup>1</sup>  
<sup>1</sup>Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy

**P138-T STRONTIUM RANELATE INCREASES OSTEOBLAST REPLICATION THROUGH ACTIVATION OF AN ORIGINAL CELLULAR MECHANISM**

J. Caverzasio\*<sup>1</sup>

<sup>1</sup>*Dept of Rehabilitation and Geriatrics, Service of Bone Diseases, Geneva, Switzerland*

**P141-T IDENTIFICATION OF NOVEL DIFFERENTIALLY EXPRESSED MEMBRANE PROTEINS BY QUANTITATIVE PROTEOMICS IN HUMAN MESENCHYMAL STEM CELLS UNDERGOING OSTEOBLAST DIFFERENTIATION**

H. Christiansen\*<sup>1</sup>, J. Burns<sup>2</sup>, I. Kratchmarova<sup>3</sup>, J. Andersen<sup>3</sup>, M. Kassem<sup>2</sup>

<sup>1</sup>*Centre for Bioinformatics CEBI and Medical Biotechnology Centre, University of Southern Denmark and Odense University Hospital, <sup>2</sup>KMEB, Dept. of Endocrinology and Metabolism, Odense University Hospital; Medical Biotechnology Centre, <sup>3</sup>Centre for Experimental Bioinformatics, University of Southern Denmark, Dept. Biochemistry and Molecular Biology, Odense, Denmark*

**P144-T** Abstract withdrawn

**P147-T RANKL ISOFORMS INFLUENCE ON THE OPG AVAILABILITY**

S. Kwan Tat<sup>1</sup>, C. Ruiz Velasco<sup>1</sup>, V. Trichet<sup>1</sup>, S. Couillaud-Battaglia<sup>1</sup>, D. Heymann<sup>1</sup>, M. Padrines\*<sup>1</sup>, Y. Fortun<sup>1</sup>

<sup>1</sup>*EA 3822-INSERM ERI 7, Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse, Nantes, France*

**P150-T THE EXPRESSION OF TWO-PORE DOMAIN POTASSIUM (K2P) CHANNELS IN OSTEOBLASTIC CELLS**

A. W. Gallagher\*<sup>1</sup>, L. Goonetilleke<sup>1</sup>, T. P. Green<sup>2</sup>, J. A. Gallagher<sup>1</sup>, J. M. Quayle<sup>1</sup>

<sup>1</sup>*Human Anatomy and Cell Biology, <sup>2</sup>Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom*

**P153-T ISOLATION OF OSTEOPROGENITOR CELLS FROM HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AND DEFINING THEIR MOLECULAR SIGNATURE**

K. Hauberg\*<sup>1</sup>, C. M. Frederiksen<sup>1</sup>, B. M. Abdallah<sup>1</sup>, J. S. Burns<sup>1</sup>, M. Kassem<sup>1</sup>

<sup>1</sup>*Dept of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark*

**P156-T OXYGEN TENSION IS AN IMPORTANT MEDIATOR OF THE TRANSFORMATION OF OSTEOBLASTS TO OSTEOCYTES**

M. Hirao\*<sup>1</sup>, J. Hashimoto<sup>1</sup>, A. Myoui<sup>1</sup>, N. Yamasaki<sup>1</sup>, W. Ando<sup>1</sup>, H. Tsuboi<sup>1</sup>, H. Yoshikawa<sup>1</sup>

<sup>1</sup>*Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan*

**P159-T NITROGEN-CONTAINING BISPHOSPHONATES INHIBIT BONE MINERALIZATION IN VITRO VIA A MECHANISM INDEPENDENT OF INHIBITION OF PROTEIN PRENYLATION**

A. I. Idris\*<sup>1</sup>, J. A. Rojas<sup>1</sup>, I. R. Greig<sup>2</sup>, R. J. van 't Hof<sup>1</sup>, S. H. Ralston<sup>1</sup>

<sup>1</sup>*Molecular Medicine Centre, University of Edinburgh, Edinburgh, <sup>2</sup>Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom*

**P162-T REDUCED PLASMA MEMBRANE ACCESS OF ANK CAUSES CRANIOMETAPHYSEAL DYSPLASIA**

J. Kühnisch\*<sup>1</sup>, J. Löbner<sup>1</sup>, S. Stumpp<sup>1</sup>, D. Epari<sup>2</sup>, M. Giehl<sup>3</sup>, H. Thiele<sup>4</sup>, D. Felsenberg<sup>3</sup>, P. Nürnberg<sup>4</sup>, S. Mundlos<sup>1</sup>, U. Kornak<sup>1</sup>

<sup>1</sup>*Charite, Institute for Medical Genetics, <sup>2</sup>Charite, Centre for Musculoskeletal Surgery, <sup>3</sup>Charite, Centre of Muscle & Bone Research, Berlin, <sup>4</sup>University of Cologne, Cologne Centre for Genomics, Köln, Germany*

**P165-T EFFECTS OF IONIZING RADIATION ON MURINE OSTEOBLASTIC CELL DIFFERENTIATION AND GENE-EXPRESSION**

P. Lau\*<sup>1</sup>, C. E. Hellweg<sup>1</sup>, C. Baumstark-Khan<sup>1</sup>, G. Reitz<sup>1</sup>

<sup>1</sup>*Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany*

**P168-T MODULATION OF THE HUMAN ESTROGEN RECEPTOR ALPHA GENE BY A C-SRC/PKC-DEPENDENT MECHANISM IN CELLS OF THE OSTEOBLAST LINEAGE**

M. Longo\*<sup>1</sup>, B. Peruzzi<sup>1</sup>, D. Fortunati<sup>1</sup>, V. De Luca<sup>1</sup>, S. Denger<sup>2</sup>, G. Caselli<sup>3</sup>, S. Migliaccio<sup>4</sup>, A. Teti<sup>1</sup>

<sup>1</sup>*Experimental Medicine, University of L'Aquila, L'Aquila, Italy, <sup>2</sup>EMBL, European Molecular Biology Laboratories, Heidelberg, Germany, <sup>3</sup>RRL, Rotta Research Laboratorium, S.p.A., Monza, <sup>4</sup>Medical Physiopathology, University of Rome "La Sapienza", Rome, Italy*

- P171-T WHOLE GENOME EXPRESSION ANALYSIS OF MG-63 OSTEOBLAST-LIKE CELL LINE UNDER DIFFERENT PHYSIOLOGICAL STIMULI**  
M. Mattioli\*<sup>1</sup>, D. Finzi<sup>1</sup>, C. Villa<sup>1</sup>, P. Tarroni<sup>1</sup>  
<sup>1</sup>Target Biology, Axxam Srl, Milan, Italy
- P174-T EFFECTS OF GLUCOCORTICOIDS ON OSTEOCYTIC GENE EXPRESSION IN VIVO AND IN VITRO**  
M. K. A. Nars\*<sup>1</sup>, G. Gu<sup>1</sup>, T. Hentunen<sup>1</sup>, K. H. Väänänen<sup>1</sup>  
<sup>1</sup>Department of Anatomy, Institute of Biomedicine, University of Turku, Turku, Finland
- P177-T ZOLEDRONATE POTENTLY INHIBITS THE GROWTH, FUNCTION AND SURVIVAL OF NORMAL RAT OSTEOBLASTS**  
I. R. Orriss\*<sup>1</sup>, J. C. Utting<sup>1</sup>, M. L. Key<sup>1</sup>, A. Brandao-Burch<sup>1</sup>, K. Colston<sup>2</sup>, T. R. Arnett<sup>1</sup>  
<sup>1</sup>Anatomy and Developmental Biology, University College London, <sup>2</sup>Oncology, Gastroenterology, Endocrinology and Metabolism, St George's Hospital Medical School, London, United Kingdom
- P180-T HETEROTOPIC OSSIFICATION IN A RADIAL FOREARM FLAP: CASE STUDY**  
E. Prempeh\*<sup>1</sup>, F. Peart<sup>2</sup>  
<sup>1</sup>Plastic Surgery, Selly Oak Hospital, Selly Oak, United Kingdom, <sup>2</sup>,
- P183-T IMMUNOHISTOCHEMICAL STUDIES DEMONSTRATE THAT GAS6 AND AXL ARE EXPRESSED BY OSTEOBLASTS AND GROWTH PLATE CHONDROCYTES**  
L. C. Ronaldson\*<sup>1</sup>, A. E. Canfield<sup>2</sup>, C. Farquharson<sup>1</sup>  
<sup>1</sup>Gene Function and Development, Roslin Institute, Midlothian, <sup>2</sup>Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
- P186-T EFFECTS OF RALOXIFENE AND ITS INTERACTION WITH HUMAN PTH ON HUMAN PRIMARY OSTEOBLASTIC CELLS**  
B. Frediani\*<sup>1</sup>, A. Spreafico<sup>1</sup>, C. Capperucci<sup>1</sup>, F. Baldi<sup>1</sup>, M. Galeazzi<sup>1</sup>, R. Marcolongo<sup>1</sup>  
<sup>1</sup>Department of Clinical Medicine and Immunological Sciences Division of Rheumatology, University of Siena, Siena, Italy
- P189-T CELLULAR SCREENING OF BONE-RELATED DISEASES IN MICE**  
F. Thiele\*<sup>1</sup>, T. S. Lisse<sup>1</sup>, G. K. H. Przemec<sup>1</sup>, H. Fuchs<sup>1</sup>, V. Gailus-Durner<sup>1</sup>, M. M. Hrabé de Angelis<sup>1</sup>  
<sup>1</sup>Institute of Experimental Genetics, GSF-National Research Center for Environment and Health, Neuherberg-Munich, Germany
- P192-T BMP-6 REGULATES GLUCOSE AND BONE METABOLISM VIA FATTY ACID AND INSULIN GROWTH FACTOR I SYNTHESIS**  
I. Orlic\*<sup>1</sup>, P. Simic<sup>1</sup>, S. Vukicevic<sup>1</sup>  
<sup>1</sup>Department of Anatomy, Medical School, Zagreb, Croatia
- P196-T THE REGULATION AND ENZYMATIC BASIS OF BONE RESORPTION BY HUMAN OSTEOCLASTS**  
K. Fuller<sup>1</sup>, B. Kirstein<sup>1</sup>, T. J. Chambers\*<sup>1</sup>  
<sup>1</sup>Cellular Pathology, St George's, University of London, London, United Kingdom
- P199-T THE LEVELS OF BONE TURNOVER MARKERS IN PERIPUBERTAL GIRLS**  
K. M. Fagerlund\*<sup>1</sup>, M. Lehtonen-Veromaa<sup>2</sup>, T. Möttönen<sup>3</sup>, H. K. Väänänen<sup>4</sup>, J. M. Halleen<sup>5</sup>  
<sup>1</sup>Institute of Biomedicine, Department of Anatomy, University of Turku, Finland, University of Turku, <sup>2</sup>Paavo Nurmi Center, Sport and Exercise Medicine Unit, Department of Physiology, University of Turku, Finland, <sup>3</sup>Department of Medicine, Turku University Central Hospital, Finland, <sup>4</sup>Institute of Biomedicine, Department of Anatomy, University of Turku, Finland, <sup>5</sup>Institute of Biomedicine, Department of Anatomy, University of Turku, Finland, Pharmatest Services Ltd, Turku, Finland
- P202-T RELEASE OF INFLAMMATORY CYTOKINES BY MONONUCLEAR CELLS FROM PERIPHERAL BLOOD UPON EXPOSURE TO METAL IONS**  
E. Hirzel<sup>1</sup>, K. Jost-Albrecht<sup>1</sup>, W. Hofstetter\*<sup>1</sup>  
<sup>1</sup>Department Clinical Research, University of Berne, Berne, Switzerland
- P205-T EFFECT OF THALIDOMIDE ON THE FORMATION OF MURINE OSTEOCLASTS IN VITRO**  
I. Kaczmarczyk-Sedlak<sup>1</sup>, J. Folwarczna\*<sup>1</sup>, L. Sliwinski<sup>1</sup>, H. I. Trzeciak<sup>1</sup>  
<sup>1</sup>Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland

- P208-T EFFECTS OF METAL IONS ON OSTEOCLASTOGENESIS**  
G. Mabilieu\*<sup>1</sup>, H. S. Gill<sup>1</sup>, A. Sabokbar<sup>1</sup>  
<sup>1</sup>*Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford, United Kingdom*
- P211-T BONE MATRIX EXTRACT DIRECTLY AND INDIRECTLY STIMULATES BONE RESORPTION**  
D. E. Powell\*<sup>1</sup>, E. Johnson<sup>2</sup>, M. J. Marshall<sup>1</sup>, J. H. H. Williams<sup>3</sup>, T. Kukita<sup>4</sup>, M. W. J. Davie<sup>1</sup>  
<sup>1</sup>*Charles Salt Research Centre, <sup>2</sup>Centre for Spinal Studies, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, <sup>3</sup>Chester Centre for Stress Research, University of Chester, Chester, United Kingdom, <sup>4</sup>Faculty of Dental Science, Kyushu University, Fukuoka, Japan*
- P214-T THE EFFECTS OF EXHAUSTIVE RUNNING EXERCISE ON BONE METABOLISM**  
J. P. R. Scott\*<sup>1</sup>, J. P. Greeves<sup>1</sup>, A. Casey<sup>1</sup>, C. Sale<sup>1</sup>, J. Dutton<sup>2</sup>, W. D. Fraser<sup>2</sup>  
<sup>1</sup>*Human Performance and Protection Enhancement, QinetiQ, Farnborough, <sup>2</sup>Department of Clinical Biochemistry, University of Liverpool, Liverpool, United Kingdom*
- P217-T HYPEROSMOLALITY DOWN-REGULATES 1ALPHA, 25-DIHYDROXYVITAMIN D3 – INDUCED OSTEOCLASTOGENESIS, SUPPRESSING THE RANKL EXPRESSION BY INHIBITING RUNX2 IN CO-CULTURE SYSTEM**  
K. Shin\*<sup>1</sup>, H. Jeong<sup>1</sup>, D. Shin<sup>1</sup>, S. Lee<sup>1</sup>  
<sup>1</sup>*Oral Biology, Oral Science Research Center, BK21 Project, Yonsei Univ College of Dentistry, Seoul, South Korea*
- P220-T DECREASING THE PREMATURE CATABOLISM BY A SINGLE BISPHOSPHONATE INFUSION SHORTENS THE HEALING TIME IN HEMICALLOTASIS OPERATIONS. A PILOT STUDY IN 24 PATIENTS**  
M. Tagil\*<sup>1</sup>, A. W-Dahl<sup>1</sup>, J. Astrand<sup>1</sup>, D. Little<sup>2</sup>, S. Toksvig-Larsen<sup>1</sup>  
<sup>1</sup>*Dep of Orthopedics, Institution of Clinical Sciences, Lund, Sweden, <sup>2</sup>Dep of Orthopedics, Childrens Hospital Westmead, Sydney, Australia*
- P223-T BONE-HEALTH RISK OF CHLOROBENZENES TREATMENT**  
Z. Valkusz\*<sup>1</sup>, G. Nagyéri<sup>2</sup>, B. Hegedűs<sup>3</sup>, A. Juhász<sup>4</sup>, A. Petri<sup>5</sup>, M. Gálfi<sup>3</sup>  
<sup>1</sup>*Endocrine Unit, <sup>2</sup>Environmental Protection Group, Faculty of Juhász Gyula Teacher Training College, University of Szeged Medical Faculty, <sup>3</sup>Environmental Protection Group, Faculty of Juhász Gyula Teacher Training College, University of Szeged, <sup>4</sup>Department of Psychiatry, <sup>5</sup>Department of Surgery, University of Szeged Medical Faculty, Szeged, Hungary*
- P226-T TRANSCRIPTIONAL REGULATION IN DEVELOPMENT OF HUMAN OSTEOCLAST**  
H. J. Vuorikoski\*<sup>1</sup>, E. Nordlund<sup>2</sup>, J. Boberg<sup>2</sup>, T. Salakoski<sup>2</sup>, T. A. Hentunen<sup>1</sup>, H. K. Väänänen<sup>1</sup>  
<sup>1</sup>*Anatomy, <sup>2</sup>Information Technology, University of Turku, Turku, Finland*
- P229-T PROMOTER 2-1025 T/C POLYMORPHISM AT RUNX2 IS ASSOCIATED WITH FEMORAL NECK BMD IN SPANISH POSTMENOPAUSAL WOMEN**  
S. Balcells\*<sup>1</sup>, M. Bustamante<sup>1</sup>, A. Wesselius<sup>1</sup>, A. Enjuanes<sup>2</sup>, X. Nogués<sup>2</sup>, L. Mellibovsky<sup>2</sup>, A. Díez-Pérez<sup>2</sup>, D. Grinberg<sup>1</sup>  
<sup>1</sup>*Genetics, Universitat de Barcelona, <sup>2</sup>Internal Medicine, URFOA, IMIM, Hospital del Mar, Barcelona, Spain*
- P232-T POLYMORPHISMS ASSOCIATION WITH OSTEOPOROSIS STUDIES PRESENT A PROBLEM CAUSED BY POPULATION STRATIFICATION IN THE MESTIZO GROUPS**  
R. Gomez\*<sup>1</sup>, J. J. Magana<sup>2</sup>, B. Cisneros<sup>2</sup>, E. Perez-Salazar<sup>3</sup>, S. Faugeron<sup>4</sup>, D. Veliz<sup>5</sup>, M. Valdes<sup>1</sup>  
<sup>1</sup>*Genetics, National Rehabilitation Institute, <sup>2</sup>Genetics and Molecular Biology, <sup>3</sup>Cell Biology, CINVESTAV-IPN, Mexico City, Mexico, <sup>4</sup>Ecology, Pontificia Universidad Catolica de Chile, <sup>5</sup>Ecology Sciences, Universidad de Chile, Santiago de Chile, Chile*
- P235-T THE GERMAN MOUSE CLINIC – DYSMORPHOLOGY, BONE AND CARTILAGE SCREEN**  
W. Hans\*<sup>1</sup>, H. Fuchs<sup>1</sup>, K. Abe<sup>2</sup>, T. Lisse<sup>1</sup>, F. Thiele<sup>1</sup>, V. Gailus-Durner<sup>1</sup>, M. Hrabé de Angelis<sup>1</sup>  
<sup>1</sup>*GSF National Research Center for Environment and Health, Institute of Experimental Genetics, Neuherberg, Germany, <sup>2</sup>Department of Molecular Life Science, Tokai University Medical School, Kanagawa, Japan*
- P238-T GAIN-OF-FUNCTION POLYMORPHISMS IN THE P2X7 PURINERGIC RECEPTOR ARE ASSOCIATED WITH INCREASED BONE MASS**  
L. B. Husted\*<sup>1</sup>, N. Gonzalez-Bofill<sup>1</sup>, M. Carstens<sup>1</sup>, L. Stenkjær<sup>1</sup>, B. L. Langdahl<sup>1</sup>  
<sup>1</sup>*Department of Endocrinology, Aarhus Sygehus, Århus, Denmark*

- P241-T EFFECT OF PVUII AND XBAI POLYMORPHISMS OF ESR1 GENE ON BODY HEIGHT IN WOMEN DEPENDS ON MENARCHE – THE EPOLOS STUDY**  
M. Kruk\*<sup>1</sup>, M. Jaworski<sup>1</sup>, J. Lukaszkiwicz<sup>2</sup>, E. Karczmarewicz<sup>1</sup>, P. Bilinski<sup>3</sup>, E. Czerwinski<sup>4</sup>, A. Lewinski<sup>5</sup>, E. Marcinowska-Suchowierska<sup>6</sup>, A. Milewicz<sup>7</sup>, M. Spaczynski<sup>8</sup>, A. G. Uitterlinden<sup>9</sup>, R. S. Lorenc<sup>1</sup>  
<sup>1</sup>Dept. of Bioch. and Exp. Med., The Children's Memorial Health Institute, <sup>2</sup>Biochemistry and Clinical Chemistry, Faculty of Pharmacy, University of Medicine, Warsaw, <sup>3</sup>Clinic of Orthopaedy and Traum., The Rydygier University of Medicine, Bydgoszcz, <sup>4</sup>Dept. of Orthopaedy, Jagiellonian University, Cracow, <sup>5</sup>Dept. of Thyroidology, Clinical Hospital No3, Lodz, <sup>6</sup>Dept. of Int. Med., The Orłowski Hospital, Warsaw, <sup>7</sup>Dept. of Endocrinology and Diabetology, University of Medicine, Wrocław, <sup>8</sup>Dept. of Gynecology, The Marcinkowski University of Medicine, Poznan, Poland, <sup>9</sup>Dept. of Int. Med., Erasmus MC, Rotterdam, Netherlands
- P244-T A NOVEL MUTATION IN TYPE I PROCOLLAGEN C-PROTEINASE CLEAVAGE SITE CAUSING “DENSE” OSTEOGENESIS IMPERFECTA**  
K. Lindahl\*<sup>1</sup>, H. Brändström<sup>1</sup>, J. Gustafsson<sup>2</sup>, J. Engvall<sup>2</sup>, Ö. Ljunggren<sup>1</sup>  
<sup>1</sup>Department of Medical Sciences, <sup>2</sup>Department of Women's and Children's Health, Uppsala University Hospital, Uppsala, Sweden
- P247-T IL-1 GENE POLYMORPHISMS AND BONE TURNOVER AFTER THE MENOPAUSE**  
K. E. Naylor\*<sup>1</sup>, J. Finigan<sup>1</sup>, J. Rogus<sup>2</sup>, K. Huttner<sup>2</sup>, L. Wilkins<sup>2</sup>, R. Eastell<sup>1</sup>  
<sup>1</sup>Academic Unit of Bone Metabolism, The University of Sheffield, Sheffield, United Kingdom, <sup>2</sup> Interleukin Genetics Inc., Waltham, United States
- P250-T EFFECTS OF THE ESTROGEN RECEPTOR, CALCITONIN RECEPTOR AND OSTEOPROTEGERIN GENES ON BONE MINERAL DENSITY, BONE-RELATED BIOCHEMICAL MARKERS AND FRACTURE INCIDENCE IN SLOVAK POSTMENOPAUSAL WOMEN**  
R. Omelka\*<sup>1</sup>, V. Krajčovičová<sup>1</sup>, D. Galbavý<sup>2</sup>, M. Martiniaková<sup>3</sup>, M. Bauerová<sup>1</sup>  
<sup>1</sup>Department of Botany and Genetics, Constantine the Philosopher University, <sup>2</sup>Private Orthopedic Ambulance, Hospital Nitra-Chrenová, <sup>3</sup>Department of Zoology and Anthropology, Constantine the Philosopher University, Nitra, Slovakia
- P253-T MUSCLE ASSOCIATED GENES ARE EXPRESSED IN HUMAN BONE BIOPSIES AND SHOW AGE AND DISEASE DEPENDENT CHANGES**  
S. Reppe\*<sup>1</sup>, O. K. Olstad<sup>2</sup>, V. T. Gautvik<sup>1</sup>, S. H. Brorson<sup>3</sup>, R. Jemtland<sup>4</sup>, F. P. Reinholt<sup>3</sup>, K. M. Gautvik<sup>2</sup>  
<sup>1</sup>Dept. of Biochemistry, Institute of Basic Medical Sciences, University of Oslo, <sup>2</sup>Dept of Clinical Chemistry, Ullevaal University Hospital, <sup>3</sup>Institute of Pathology, <sup>4</sup>Endocrine Section, Dept of Medicine, National University Hospital, Oslo, Norway
- P256-T TRAF6 GENE VARIANTS IN A FAMILY WITH A HIGHLY PENETRANT FORM OF OSTEOPOROSIS**  
C. Vidal\*<sup>1</sup>, R. Galea<sup>2</sup>, M. Brincat<sup>2</sup>, X. Angela<sup>3</sup>  
<sup>1</sup>Department of Pathology, <sup>2</sup>Department of Obstetrics and Gynaecology, <sup>3</sup>Institute of Health Care, University of Malta, G Mangia, Malta
- P260-T SEVERE VITAMIN D DEFICIENCY IN OSTEOARTHRITIC PATIENTS IS ASSOCIATED WITH LESS IMPROVEMENT IN DAILY FUNCTIONING AFTER TOTAL KNEE AND HIP ARTHROPLASTY**  
S. A. Vreugdenhil<sup>1</sup>, M. Huisman<sup>1</sup>, J. M. W. Hazes<sup>2</sup>, H. C. van Paassen<sup>1</sup>, E. M. Colin\*<sup>2</sup>  
<sup>1</sup>Rheumatology, Sint Franciscus Gasthuis, <sup>2</sup>Rheumatology, Erasmus MC, Rotterdam, Netherlands
- P263-T EFFECT OF KOREAN RED GINSENG ON LIPID PROFILES AND AORTIC VASCULAR(ENDOTHELIAL) PATHOLOGIC CHANGES FOR 3 MONTHS COMPARED WITH CHINESE RED GINSENG AND CONTROL IN RATS**  
I. Joo<sup>1</sup>, H. Oh\*<sup>1</sup>, B. Yu<sup>2</sup>, K. Kim<sup>3</sup>  
<sup>1</sup>Family Medicine, Cheilgeneral Hospital, Seoul, <sup>2</sup>Family Medicine, Guryang University, Taejeon, <sup>3</sup>Family Medicine, Catholic University, Seoul, South Korea
- P266-T THE LOWER DOSE OF OESTROGEN IS ABLE TO PREVENT POSTMENOPAUSAL BONE LOSS**  
L. A. Marchenkova\*<sup>1</sup>, A. V. Dreval<sup>1</sup>, I. V. Kryukova<sup>1</sup>  
<sup>1</sup>Department of Endocrinology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation
- P269-T VITAMIN D METABOLITES AND SKELETAL CONSEQUENCES IN PRIMARY**



## **HYPERPARATHYROIDISM**

B. Moosgaard<sup>1</sup>, P. Vestergaard<sup>1</sup>, L. Heickendorff<sup>2</sup>, L. Mosekilde<sup>1</sup>

<sup>1</sup>*Dept of Endocrinology and Metabolism, <sup>2</sup>Dept of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark*

## **P272-T DEVELOPMENT OF THE LIAISON® 25-OH VITAMIN D TOTAL ASSAY WITH IMPROVED SENSITIVITY AND PRECISION**

G. T. Olson<sup>1</sup>, E. Frenzel<sup>1</sup>, M. Friedberg<sup>1</sup>, J. Fenske<sup>1</sup>, D. S. Rao<sup>2</sup>, P. J. Terhaar<sup>1</sup>, A. Podgorski<sup>1</sup>, D. Vaught<sup>1</sup>, J. A. Schmidt<sup>1</sup>

<sup>1</sup>*Research and Development, DiaSorin, Stillwater, <sup>2</sup>Bone and Mineral Research Laboratory, Henry Ford Hospital, Detroit, United States*

## **P275-T GLOBAL SERUM 25-HYDROXY-VITAMIN D LEVELS: A META-ANALYSIS**

C. S. Poulsen<sup>1</sup>, T. Hagenau<sup>1</sup>, R. Vest<sup>1</sup>, T. N. Gissel<sup>1</sup>, M. Erlandsen<sup>2</sup>, L. Mosekilde<sup>1</sup>, P. Vestergaard<sup>1</sup>

<sup>1</sup>*Department of Endocrinology and Metabolism C, Aarhus Sygehus, <sup>2</sup>Department of Biostatistics, Aarhus University, Aarhus, Denmark*

## **P278-T TYPE OF HIP FRACTURE AND VITAMIN D STATUS IN ELDERLY HIP FRACTURE PATIENTS**

E. Segal<sup>1</sup>, C. Zinman<sup>2</sup>, B. Raz<sup>1</sup>, S. Ish-Shalom<sup>1</sup>

<sup>1</sup>*Bone Metabolic Diseases Unit, <sup>2</sup>Orthopedic Surgery Department, Rambam Health Care Campus, Haifa, Israel*

## **P281-T CALCIMIMETIC DRUG AMG 073 INDUCES RELAXATION OF THE ISOLATED RAT AORTA**

S. Smajilovic<sup>1</sup>, M. Sheykhzade<sup>2</sup>, S. Haunso<sup>1</sup>, J. Tfelt-Hansen<sup>1</sup>

<sup>1</sup>*Laboratory of Molecular Cardiology, Copenhagen University Hospital, <sup>2</sup>Department of Pharmacology, The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark*

## **P284-T Abstract withdrawn**

## **P287-T BONE LOSS IN PREMENOPAUSAL WOMEN WITH HYPERTHYREOSIS**

T. Turk<sup>1</sup>, I. Smoljan<sup>1</sup>, K. Bazdaric<sup>2</sup>, Z. Crncevic-Orlic<sup>1</sup>

<sup>1</sup>*Endocrinology, Diabetes and Metabolic Diseases, Clinical Hospital Centre Rijeka, Croatia, <sup>2</sup>Department of Medical Informatics, School of Medicine, University of Rijeka, Rijeka, Croatia*

## **P290-T EFFECTS OF VITAMIN D3 8400 IU ONCE WEEKLY ON BODY SWAY OF ELDERLY SUBJECTS WITH VITAMIN D INSUFFICIENCY**

P. Lips<sup>1</sup>, M. Pfeifer<sup>2</sup>, J. Walliser<sup>3</sup>, A. Holst<sup>4</sup>, N. Binkley<sup>5</sup>, R. Recker<sup>6</sup>, K. Krohn<sup>7</sup>, M. Liu<sup>8</sup>, D. Cohn<sup>8</sup>, L. E. Wehren<sup>9</sup>, D. Papanicolaou<sup>8</sup>

<sup>1</sup>*Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands, <sup>2</sup>Klinik der Furstenhof, Bad Pyrmont, Germany, <sup>3</sup>Hospital Angeles del Pedregal, Mexico City, Mexico, <sup>4</sup>Clinical Research Hamburg, Hamburg, Germany, <sup>5</sup>University of Wisconsin, Madison, WI, <sup>6</sup>Creighton University, Omaha, NE, <sup>7</sup>MCR Rheumatology Associates, Pittsburgh, PA, <sup>8</sup>Merck Research Laboratories, Rahway, NJ, <sup>9</sup>Medical Communications, Merck Research Laboratories, Rahway, United States*

## **P293-T TERIPARATIDE: THE IMPACT ON THE QUALITY OF LIFE**

A. Amedei<sup>1</sup>, L. Masi<sup>1</sup>, C. Casentini<sup>1</sup>, M. Barbagli<sup>2</sup>, M. Brandi<sup>1</sup>

<sup>1</sup>*Department of Internal Medicine, University of Florence, <sup>2</sup>Casa di Cura, Villa Donatello, Florence, Italy*

## **P296-T PROXIMAL HUMERUS FRACTURES IN PATIENTS BETWEEN 50 AND 65 YEARS CAUSE INFERIOR SUBJECTIVE OUTCOME. STRONGER INDICATION FOR ACTIVE SURGICAL TREATMENT?**

J. Åstrand<sup>1</sup>

<sup>1</sup>*Department of Orthopaedics, Lund University, Lund, Sweden*

## **P299-T NON-INVASIVE MEASUREMENT OF BONE STRONTIUM DURING LONG-TERM TREATMENT WITH STRONTIUM RANELATE**

O. Bärenholdt<sup>1</sup>, N. Kolthoff<sup>1</sup>, S. Pors Nielsen<sup>1</sup>

<sup>1</sup>*Bone Unit, Dept. of Clinical Physiology, Hilleroed Hospital, Hilleroed, Denmark*

## **P302-T ANALGESIC EFFICACY OF CALCITONIN FOR VERTEBRAL FRACTURE PAIN**

A. Bazarra-Fernández<sup>1</sup>

<sup>1</sup>*ObGyn, Juan Canalejo University Hospital Trust, Culleredo, Spain*

**P305-T COMBINED VERTEBRAL STABILIZATION BY MEANS OF CEMENT-AUGMENTED POSTERIOR INSTRUMENTATION AND BALLOON-KYPHOPLASTY IN OSTEOPOROTIC BURST FRACTURES**

T. R. Blatter\*<sup>1</sup>, S. Katscher<sup>1</sup>, S. Glasmacher<sup>1</sup>, C. Josten<sup>1</sup>

<sup>1</sup>Trauma, Reconstructive, and Plastic Surgery, Leipzig University Hospital, Leipzig, Germany

**P308-T WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS OR OSTEOPENIA PREVIOUSLY RECEIVING WEEKLY ALENDRONATE OR RISEDRONATE ARE MORE SATISFIED WITH MONTHLY IBANDRONATE**

S. L. Bonnick\*<sup>1</sup>, M. Martens<sup>2</sup>, R. Civitelli<sup>3</sup>, K. E. Friend<sup>4</sup>, S. Silverman<sup>5</sup>

<sup>1</sup>Department of Medicine, Clinical Research Center of North Texas, Denton, <sup>2</sup>OB/GYN Infectious Disease Division, University of Oklahoma, Tulsa, <sup>3</sup>Division of Bone and Mineral Diseases, Washington University School of Medicine, St Louis, <sup>4</sup>US Medical Affairs, Roche Laboratories, Nutley, <sup>5</sup>Medicine and Rheumatology, Cedars-Sinai/UCLA, Beverly Hills, United States

**P311-T WORK-UP FOR SECONDARY CAUSES OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN. PRELIMINARY RESULTS**

D. Cerdà\*<sup>1</sup>, P. Peris<sup>2</sup>, A. Monegal<sup>2</sup>, C. Albaladejo<sup>3</sup>, M. Martínez<sup>2</sup>, F. Pons<sup>4</sup>, M. Martínez de Osaba<sup>4</sup>, X. Suris<sup>1</sup>, N. Guañabens<sup>2</sup>

<sup>1</sup>Rheumatology Department, Hospital General de Granollers, Granollers, <sup>2</sup>Rheumatology Department, Hospital Clínic, <sup>3</sup>Rheumatology Department, CAP Manso, <sup>4</sup>Hospital Clínic, Barcelona, Spain

**P314-T DISSOCIATION BETWEEN BONE FORMATION AND BONE RESORPTION EVIDENCED BY CHANGES IN BIOCHEMICAL MARKERS OF BONE TURNOVER IN PATIENTS TREATED WITH STRONTIUM RANELATE**

J. Collette\*<sup>1</sup>, J. Y. Reginster<sup>2</sup>, O. Bruyère<sup>2</sup>, R. Deroisy<sup>2</sup>, I. Jupsin<sup>2</sup>, J. P. Devogelaer<sup>3</sup>, S. Adami<sup>4</sup>, C. Marcelli<sup>5</sup>

<sup>1</sup>Department of Clinical Biology, Bone and Cartilage Markers Laboratory, University of Liège, <sup>2</sup>Unité d'Exploration du Métabolisme Osseux, CHU BRULL, Liège, <sup>3</sup>Service Rhumatologie, Louvain Catholic University, Brussels, Belgium, <sup>4</sup>Servizio di Reumatologia, University of Verona, Verona, Italy, <sup>5</sup>Department of Rheumatology, Caen University Hospital, Caen, France

**P317-T COMBINED RALOXIFENE TO TERIPARATIDE TREATMENT PROMPTLY IMPROVES BMD IN MULTIFRACTURED PATIENTS NON-RESPONDER TO ANTIRESORPTIVES**

G. M. D'Avola\*<sup>1</sup>, D. D'Avola<sup>2</sup>

<sup>1</sup>Rheumatology, Azienda Sanitaria Locale 3 Catania, Catania, <sup>2</sup>Internal Medicine, Campus Bio-Medico University, Rome, Italy

**P320-T RISEDRONATE AND ALENDRONATE FOR THE REDUCTION OF HIP AND NONVERTEBRAL FRACTURES, A RETROSPECTIVE COHORT STUDY**

P. D. Delmas\*<sup>1</sup>, S. L. Silverman<sup>2</sup>, N. B. Watts<sup>3</sup>, J. L. Lange<sup>4</sup>, R. Lindsay<sup>5</sup>

<sup>1</sup>INSERM Unit 403, Université Claude Bernard Lyon 1, Lyon, France, <sup>2</sup>Cedars Sinai Medical Center, David Geffen School of Medicine, UCLA, Beverly Hills, CA, <sup>3</sup>Bone Health & Osteoporosis Center, University of Cincinnati, Cincinnati, OH, <sup>4</sup>Procter & Gamble Pharmaceuticals, Mason, OH, <sup>5</sup>Helen Hayes Hospital, West Haverstraw, NY, United States

**P323-T CAN DXA ACCURATELY MEASURE ABDOMINAL FAT? COMPARISON WITH MRI AND ANTHROPOMETRIC ASSESSMENT**

S. Di Gregorio\*<sup>1</sup>, L. Del Rio<sup>1</sup>, L. Ibañez<sup>2</sup>, C. Sole<sup>1</sup>, E. Bonel<sup>1</sup>, M. Garcia<sup>1</sup>

<sup>1</sup>CETIR, Centre Medic, <sup>2</sup>Hospital, Sant Joan de Déu, Barcelona, Spain

**P326-T COMMUNITY BONE DENSITOMETRY: INFLUENCE ON TREATMENT INITIATION AND COMPLIANCE?**

M. N. Dugard\*<sup>1</sup>, T. Jones<sup>1</sup>, K. Penry<sup>1</sup>, T. D. Ryan<sup>1</sup>, H. C. Williams<sup>1</sup>, M. W. J. Davie<sup>1</sup>

<sup>1</sup>Charles Salt Research Centre, RJ and AH Orthopaedic Hospital, Oswestry, United Kingdom

**P329-T SECONDARY PREVENTION OF OSTEOPOROTIC FRACTURES: PROBLEMS IN OSTEOPOROSIS TREATMENT IN REAL LIFE. (PARTIAL RESULTS)**

H. Eichbauer\*<sup>1</sup>, E. Zwettler<sup>1</sup>, W. Scharf<sup>2</sup>, K. Klaushofer<sup>1</sup>

<sup>1</sup>4<sup>th</sup> Medical Department, <sup>2</sup>Accident Ward, Hanusch-Hospital, Vienna, Austria

**P332-T A NEW COMBINATION PACKAGING FOR OSTEOPOROSIS TREATMENT; PATIENT PREFERENCE AND EXPECTED ADHERENCE TO THE THERAPY**

P. Fardellone\*<sup>1</sup>, B. Mann<sup>2</sup>

<sup>1</sup>Department of Rheumatology, CHU, AMIENS, France, <sup>2</sup>, Procter & Gamble Pharmaceuticals, Schwalbach, Germany

- P335-T SEQUENTIAL TREATMENT WITH FULL-LENGTH PARATHYROID PTH(1-84) OF POSTMENOPAUSAL WOMEN WITH PRIMARY OSTEOPOROSIS**  
D. Felsenberg\*<sup>1</sup>, P. Delmas<sup>2</sup>, D. Hosking<sup>3</sup>, R. Rizzoli<sup>4</sup>, M. Brandi<sup>5</sup>, M. Diaz-Curiel<sup>6</sup>, L. H. Hyldstrup<sup>7</sup>  
<sup>1</sup>Benjamin Franklin Zentrum für Muskel-und Knochenforschung, Charité ,University Hospital, Berlin, Germany, <sup>2</sup>Inserm, University Hospital, Lyon, France, <sup>3</sup>University Hospital, David Evans Medical Research Center, Nottingham, United Kingdom, <sup>4</sup>Department of Rehabilitation and Geriatrics, University Hospital, Geneva, Switzerland, <sup>5</sup>Department of Internal Medicine, Metabolic Unit, Firenze, Italy, <sup>6</sup>Servicio de Medicina Interna, Universidad Autonoma, Madrid, Spain, <sup>7</sup>International Medical Affaires, Nycomed, Roskilde, Denmark
- P338-T ORAL IBANDRONATE IMPROVES HIP STRUCTURAL PARAMETERS IN THE BONE STUDY**  
T. Fuerst\*<sup>1</sup>, T. J. Beck<sup>2</sup>, K. Gaither<sup>1</sup>, M. Kothari<sup>1</sup>, H. K. Genant<sup>3</sup>  
<sup>1</sup>Osteoporosis, Synarc Inc., San Francisco, <sup>2</sup>The Johns Hopkins Outpatient Center, Johns Hopkins University, Philadelphia, <sup>3</sup>Department of Radiology, Synarc Inc. & University of California, San Francisco, United States
- P341-T INSUFFICIENCY SUBTROCHANTERIC FRACTURES IN PATIENTS ON ALENDRONATE THERAPY: A CAUTION**  
S. Goh\*<sup>1</sup>, J. Koh<sup>1</sup>, K. Yang<sup>1</sup>, M. Wong<sup>1</sup>, T. Howe<sup>1</sup>  
<sup>1</sup>Orthopaedic Surgery, Singapore General Hospital, Singapore, Singapore
- P344-T QUANTITATIVE ULTRASOUND IN THE MONITORING THE EFFECTS ON BONE OF TERIPARATIDE AND ANTIRESORPTIVE DRUGS**  
S. Gonnelli\*<sup>1</sup>, G. Martini<sup>1</sup>, C. Caffarelli<sup>1</sup>, C. Peropan<sup>1</sup>, C. Guerriero<sup>1</sup>, S. Salvadori<sup>1</sup>, A. Montagnani<sup>1</sup>, R. Nuti<sup>1</sup>  
<sup>1</sup>Department of Internal Medicine, Endocrine-Metabolic Science and Biochemistry, University of Siena, Siena, Italy
- P347-T EFFECTS OF TERIPARATIDE TREATMENT IN OSTEOPOROTIC PATIENT WITH PREVIOUS CANCER PATHOLOGY**  
M. Greggi\*<sup>1</sup>, V. Chiatti<sup>1</sup>, M. Sbardella<sup>1</sup>  
<sup>1</sup>Orthopedic Departement, S.Anna Clinic, Pomezia, Italy
- P350-T BISPHOSPHONATES STIMULATE LINEAR GROWTH OF FETAL RAT METATARSAL BONES AND PROTECT CHONDROCYTES FROM DEXAMETHASONE-INDUCED APOPTOSIS**  
T. J. Heino\*<sup>1</sup>, A. S. Chagin<sup>1</sup>, L. Sävendahl<sup>1</sup>  
<sup>1</sup>Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden
- P353-T AGING OF CORTICAL BONE IN MEN AND WOMEN. A CROSS-SECTIONAL STUDY OF METACARPAL CORTICAL DIMENSIONS IN 4100 NORMAL SUBJECTS USING DIGITAL X-RAY RADIOGRAMMETRY**  
L. Hyldstrup\*<sup>1</sup>, P. Bach-Mortensen<sup>1</sup>, S. Sonne-Holm<sup>2</sup>, T. W. Jensen<sup>1</sup>  
<sup>1</sup>Dept of Endocrinology, <sup>2</sup>Dept. of Orthopedic Surgery, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
- P356-T COMPARISON OF VERTEBRAL AREA, BMC AND BMD IN OLDER WOMEN UTILIZING THE REGULAR-LATERAL OR MORPHOMETRIC SCANS BY iDXA**  
J. Z. Ilich\*<sup>1</sup>, P. Liu<sup>1</sup>, A. P. Crombie<sup>1</sup>  
<sup>1</sup>Nutrition, Food and Exercise Sciences, Florida State University, Tallahassee, United States
- P359-T BIOCHEMICAL MARKERS OF BONE TURNOVER; INITIAL RESPONSE TO PTH 1-34 TREATMENT AND RELATION TO CHANGES IN BMD AND BMC**  
J. B. Jensen\*<sup>1</sup>, M. Hitz<sup>1</sup>, N. R. Jørgensen<sup>1</sup>, P. Schwarz<sup>1</sup>, L. Hyldstrup<sup>1</sup>  
<sup>1</sup>Osteoporosis and Calcium Metabolic Research Unit, Hvidovre University Hospital, Hvidovre, Denmark
- P362-T LIPID PROFILE CHANGES IN POSTMENOPAUSAL KOREAN WOMEN TREATED WITH ALENDRONATE(10MG) FOR 2 YEARS**  
I. Joo\*<sup>1</sup>, H. Oh<sup>1</sup>, B. Yu<sup>2</sup>, K. Kim<sup>3</sup>  
<sup>1</sup>Family Medicine, Cheilgeneral Hospital, Seoul, <sup>2</sup>Family Medicine, Gonyang University, Taejeon, <sup>3</sup>Family Medicine, Catholic University, Seoul, South Korea
- P365-T DIFFERENCES IN PHYSICAL PERFORMANCE WHEN COMPARING MEN AGED 70-80 YEARS**

**WITH AND WITHOUT SELF-REPORTED FALLS – BASELINE DATA FROM THE POPULATION-BASED MROS STUDY**

E. Ljunggren-Ribom\*<sup>1</sup>, E. Grundberg<sup>1</sup>, A. Holmberg<sup>2</sup>, D. Mellström<sup>3</sup>, E. Orwoll<sup>4</sup>, Ö. Ljunggren<sup>1</sup>, M. K. Karlsson<sup>2</sup>

<sup>1</sup>Department of Surgical Sciences, University Hospital, Uppsala, <sup>2</sup>Department of Orthopaedics, Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences, Lund University, Malmö, <sup>3</sup>Center for Bone Research, Departments of Internal Medicine and Geriatrics, Sahlgrenska Academy, Gothenburg, Sweden, <sup>4</sup>Bone and Mineral Unit, Oregon Health & Science University, Portland, United States

**P368-T DESPITE OF MANY INFORMATION CAMPAIGNS, OSTEOPOROSIS REMAINS UNDERDIAGNOSED AND UNDERTREATED IN SWITZERLAND**

C. Krieg\*<sup>1</sup>, J. Scholler<sup>1</sup>, T. Monod<sup>1</sup>, M. Krieg<sup>1</sup>

<sup>1</sup>Bone Diseases Unit, South Fribourg Hospital, Riaz, Switzerland

**P371-T IBANDRONATE IS WELL TOLERATED BY PATIENTS INTOLERANT OF WEEKLY ALENDRONATE OR RISEDRONATE: RESULTS FROM THE PRIOR STUDY**

A. Laster\*<sup>1</sup>, S. L. Bonnick<sup>2</sup>, K. E. Friend<sup>3</sup>, E. M. Lewiecki<sup>4</sup>

<sup>1</sup>Chair Public Policy ISCD, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, <sup>2</sup>Department of Medicine, Clinical Research Center of North Texas, Denton, <sup>3</sup>US Medical Affairs, Roche Laboratories, Nutley, <sup>4</sup>New Mexico Clinical Research, Osteoporosis Center, Albuquerque, United States

**P374-T THE EFFECTS OF LOW-INTENSITY PULSED ULTRASOUND ON PREVENTING THE DISUSE OSTEOPOROSIS IN RATS**

M. Q. Liu\*<sup>1</sup>, X. Guo<sup>1</sup>, X. Y. Wang<sup>1</sup>, K. S. C. Kwong<sup>1</sup>, M. Z. Qian<sup>2</sup>

<sup>1</sup>Department of Rehabilitation Sciences, <sup>2</sup>Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, Hong Kong Special Administrative Region of China

**P377-T LONG-TERM BENEFICIAL EFFECTS OF STRONTIUM RANELATE ON THE QUALITY OF LIFE IN PATIENTS WITH VERTEBRAL OSTEOPOROSIS (SOTI STUDY)**

P. Marquis\*<sup>1</sup>, C. Roux<sup>2</sup>, M. Diaz-Curiel<sup>3</sup>, C. Cormier<sup>4</sup>, G. Isaia<sup>5</sup>, J. Badurski<sup>6</sup>, J. D. Wark<sup>7</sup>

<sup>1</sup>Mapi Values, MAPI, Boston, United States, <sup>2</sup>Service de Rhumatologie B, Hôpital Cochin, Paris, France, <sup>3</sup>Servicio de Medicina Interna, Jimenez Diaz Foundation, Madrid, Spain, <sup>4</sup>Service de Rhumatologie A, Hôpital Cochin, Paris, France, <sup>5</sup>Departimento Medicina Interna, Divisione Universitaria di Medicina Generale, Torino, Italy, <sup>6</sup>Department of Medicine & Rheumatology, Polish Center of Osteoporosis, Bialystok, Poland, <sup>7</sup>Department of Medicine, Royal Melbourne Hospital, Parkville Victoria, Australia

**P380-T THE EFFECT OF PRIOR BISPHOSPHONATE EXPOSURE ON THE EARLY TREATMENT RESPONSE TO TERIPARATIDE IN CLINICAL PRACTICE**

E. T. Middleton\*<sup>1</sup>, S. M. Doherty<sup>1</sup>, S. A. Steel<sup>1</sup>

<sup>1</sup>Centre for Metabolic Bone Disease, Hull Royal Infirmary, Hull, United Kingdom

**P383-T DIFFERENT STRATEGIES FOR MONITORING THE BIOCHEMICAL RESPONSE TO RALOXIFENE THERAPY: RELATIONSHIP TO CHANGES IN BONE MINERAL DENSITY**

K. E. Naylor\*<sup>1</sup>, J. A. Clowes<sup>1</sup>, J. Finigan<sup>1</sup>, M. A. Paggiosi<sup>1</sup>, N. F. A. Peel<sup>2</sup>, R. Eastell<sup>1</sup>

<sup>1</sup>Academic Unit of Bone Metabolism, The University of Sheffield, <sup>2</sup>Metabolic Bone Centre, Northern General Hospital, Sheffield, United Kingdom

**P386-T BIOCHEMICAL MARKERS OF BONE TURNOVER PREDICT BMD CHANGES AT CORTICAL AND CANCELLOUS SITES IN A 16-MONTH STUDY OF DENOSUMAB (A FULLY HUMAN RANKL ANTIBODY) IN AGED OVARECTOMIZED CYNOMOLGUS MONKEYS**

M. S. Ominsky\*<sup>1</sup>, S. Y. Smith<sup>2</sup>, D. J. Farrell<sup>2</sup>, J. Schroeder<sup>3</sup>, J. E. Atkinson<sup>3</sup>, P. J. Kostenuik<sup>1</sup>

<sup>1</sup>Metabolic Disorders, Amgen Inc, Thousand Oaks, United States, <sup>2</sup>Charles River Laboratories Preclinical Services Montreal, Inc, Montreal, Canada, <sup>3</sup>Toxicology, Amgen Inc, Thousand Oaks, United States

**P389-T THE MICRODAMAGE ACCUMULATION IS MORE FREQUENT IN PATIENTS WITH IMPAIRED TRABECULAR BONE MICROSTRUCTURE**

I. Pavo\*<sup>1</sup>, J. J. Stepan<sup>2</sup>, J. Li<sup>3</sup>, D. Michalská<sup>2</sup>, A. Sipos<sup>4</sup>, H. Petto<sup>1</sup>, D. B. Burr<sup>3</sup>, H. Dobnig<sup>5</sup>

<sup>1</sup>Area Medical Center Vienna, Eli Lilly Regional Operations, Vienna, Austria, <sup>2</sup>Internal Medicine 3, Faculty of Medicine, Charles University, Prague, Czech Republic, <sup>3</sup>Department of Anatomy and Cell Biology, Indiana University School of Medicine, <sup>4</sup>Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, United States, <sup>5</sup>Internal Medicine, Medical University, Graz, Austria

**P392-T A COMPUTER-BASED MEASURE OF IRREGULARITY IN VERTEBRAL ALIGNMENT IS A**

**BMD-INDEPENDENT PREDICTOR OF FRACTURE RISK IN POSTMENOPAUSAL WOMEN**

P. C. Pettersen\*<sup>1</sup>, M. de Bruijne<sup>2</sup>, J. Chen<sup>1</sup>, Q. He<sup>1</sup>, C. Christiansen<sup>3</sup>, L. B. Tankó<sup>3</sup>

<sup>1</sup>Radiology, Center for Clinical and Basic Research, Ballerup, <sup>2</sup>Image Analysis, IT University of Copenhagen, Copenhagen S, <sup>3</sup>Clinical Science, Center for Clinical and Basic Research, Ballerup, Denmark

**P395-T REGIONAL THINNING OF CORTICAL BONE IN THE FEMORAL NECK IN HEMIPLEGIA: A PILOT STUDY**

K. E. S. Poole\*<sup>1</sup>, C. M. Rose<sup>1</sup>, S. Kaptoge<sup>1</sup>, J. K. Brown<sup>2</sup>, N. Loveridge<sup>1</sup>, J. Reeve<sup>1</sup>

<sup>1</sup>Division of Bone Research, University of Cambridge, Cambridge, United Kingdom, <sup>2</sup>Mindways Software, Inc., Austin, Texas, United States

**P398-T INSUFFICIENCIES IN TREATED AND NON-TREATED POSTMENOPAUSAL OSTEOPOROTIC SPANISH WOMEN: CALCIUM INTAKE AND SERUM VITAMIN D. THE PREVICAD STUDY**

J. M. Quesada Gómez\*<sup>1</sup>, J. Delgado<sup>2</sup>, E. Ramírez<sup>3</sup>

<sup>1</sup>Servicio de Endocrinología, Hospital Universitario Reina Sofía, Córdoba, <sup>2</sup>Medical Department, Procter & Gamble Pharmaceutical Iberia, <sup>3</sup>Medical Writing, Infociencia, Barcelona, Spain

**P401-T FAVOURABLE TOLERABILITY WITH CONTINUED ADMINISTRATION OF QUARTERLY INTRAVENOUS IBANDRONATE INJECTIONS: THE DIVA STUDY LONG-TERM EXTENSION**

D. M. Reid\*<sup>1</sup>, L. Hyldstrup<sup>2</sup>, P. Garcia-Hernandez<sup>3</sup>, R. Grant<sup>4</sup>, C. Neate<sup>5</sup>, C. Leigh<sup>5</sup>, S. Adami<sup>6</sup>

<sup>1</sup>Department of Medicine and Therapeutics, University of Aberdeen Medical School, Aberdeen, United Kingdom, <sup>2</sup>Dept. of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark, <sup>3</sup>Endocrinology Service/Osteoporosis Center, University Hospital, Monterrey, Mexico, <sup>4</sup>Inflammatory and Bone Diseases, Hoffmann-La Roche Inc., Nutley, United States, <sup>5</sup>Pharma-Development Medical Biostatistics, Roche Products Ltd, Welwyn Garden City, United Kingdom, <sup>6</sup>Department of Rheumatology, University of Verona, Verona, Italy

**P404-T THE IMPACT OF OSTEOPOROSIS ON PERIPROSTHETIC BONE MINERAL DENSITY**

S. S. Rodionova\*<sup>1</sup>, I. V. Klyushnitchenko<sup>1</sup>

<sup>1</sup>Research Centre for Osteoporosis, Central Institute of Traumatology and Orthopaedics, Moscow, Russian Federation

**P407-T SUSTAINED EFFECT OF PTH (1-84) ON RISK OF VERTEBRAL FRACTURES 12 MONTHS AFTER CESSATION OF THERAPY**

C. Roux\*<sup>1</sup>, J. Clausen<sup>2</sup>

<sup>1</sup>CHU Cochin, Service Rhumatologie, Paris, France, <sup>2</sup>International Medical Affairs, Nycomed, Roskilde, Denmark

**P410-T LOW LEVELS OF FREE TESTOSTERONE INDEX ARE SIGNIFICANTLY ASSOCIATED WITH OSTEOPOROSIS IN MEN WITH HIP FRACTURES. RESULTS FROM A 1 YEAR POPULATION BASED COHORT**

J. Ryg\*<sup>1</sup>, T. Nielsen<sup>1</sup>, S. Overgaard<sup>2</sup>, M. Andersen<sup>1</sup>, K. Brixen<sup>1</sup>

<sup>1</sup>Department of Endocrinology, <sup>2</sup>Department of Orthopedic Surgery, Odense University Hospital, Odense, Denmark

**P413-T THREE YEARS EXPERIENCE WITH THE CLINICAL USE OF BALLOON KYPHOPLASTY**

J. U. Schulz\*<sup>1</sup>

<sup>1</sup>Abtl. für Orthopädie und Traumatologie, Katholische Kliniken Oberberg Ggmbh St. Josef Krankenhaus Engelskirchen, Engelskirchen, Germany

**P416-T MEASUREMENT OF QUALITY OF LIFE (QOL) IN PATIENTS ENROLLED IN THE ICARO STUDY (INCIDENCE AND CHARACTERIZATION OF "INADEQUATE TREATMENT RESPONDER PATIENTS" IN OSTEOPOROSIS): RESULTS AT FOLLOW-UP AFTER 12 MONTHS**

L. Dalle Carbonare<sup>1</sup>, F. Cantatore<sup>2</sup>, G. Lentini<sup>3</sup>, S. Silvestri\*<sup>4</sup>, R. Gentilella<sup>4</sup>, G. D'Avola<sup>5</sup>, V. Lucchese for the ICARO study Group<sup>6</sup>

<sup>1</sup>Medicina Interna, Università di Padova, Padova, <sup>2</sup>Clinica Reumatologica, Universitaria, Ospedali Riuniti di Foggia, Foggia, <sup>3</sup>Ostetricia e Ginecologia, Ospedale Buccheri La Ferla FBF, Palermo, <sup>4</sup>Medical Dept., Eli Lilly Italia, Sesto Fiorentino, <sup>5</sup>Poliambulatorio di Reumatologia, AUSL 3, Catania, <sup>6</sup>Medicina Riabilitativa, Ospedale Estense, Modena, Italy

**P419-T BONE MINERAL DENSITY, MOTOR FUNCTION AND MUSCLE STRENGTH IN DUCHENNE MUSCULAR DYSTROPHY**

A. Söderpalm\*<sup>1</sup>, A. Kroksmark<sup>2</sup>, P. Magnusson<sup>3</sup>, A. Åhlander<sup>2</sup>, J. Karlsson<sup>1</sup>, M. Tulinius<sup>2</sup>, D. Swolin-Eide<sup>2</sup>

<sup>1</sup>Dept of Orthopaedics, <sup>2</sup>Dept of Paediatrics, Inst for Clinical Sciences, Gothenburg, <sup>3</sup>Div of Clinical Chemistry, Faculty of Health Sciences, Linköping, Sweden

**P422-T PERIPHERAL LEPTIN ADMINISTRATION TO NORMAL FEMALE RATS MAINTAINS BONE MINERAL DENSITY, BONE ARCHITECTURE AND MECHANICAL STRENGTH IN SPITE OF SIGNIFICANT WEIGHT LOSS**

U. Syversen\*<sup>1</sup>, I. Westbroek<sup>2</sup>, A. K. Stunes<sup>1</sup>, B. Gustafsson<sup>3</sup>, H. van Leeuwen<sup>2</sup>, H. Weinans<sup>2</sup>, J. E. Reseland<sup>4</sup>  
<sup>1</sup>Dept of Cancer Research and Mol. Medicine, Norwegian University of Science and Technology, Trondheim, Norway, <sup>2</sup>Dept of Orthopaedics and Internal Medicine, Erasmus University, Rotterdam, Netherlands, <sup>3</sup>Dept of Gastroenterology, St Olav's University Hospital HF, Trondheim, <sup>4</sup>Dept of Biomaterials, Institute for Clinical Dentistry, University of Oslo, Oslo, Norway

**P425-T EFFECTIVE TRACING OF OSTEOPOROSIS AT A FRACTURE AND OSTEOPOROSIS SCREENING PROGRAM IN GP-PRACTICE, EXPERIENCE WITH A MOBILE DEXA FACILITY**

A. Verhage\*<sup>1</sup>, W. Jaspers<sup>2</sup>  
<sup>1</sup>Internal Medicine, St. Lucas Hospital, Winschoten, <sup>2</sup>Stichting Transmuraal Netwerk, Osteology, Scheemda, Netherlands

**P428-T SEVELAMER RESTORES BONE QUALITY IN OVARIECTOMIZED RATS**

N. Draca\*<sup>1</sup>, A. Tikvica<sup>1</sup>, P. Simic<sup>1</sup>, M. Brncic<sup>2</sup>, D. Semenski<sup>3</sup>, K. T. Sampath<sup>4</sup>, S. Vukicevic<sup>1</sup>  
<sup>1</sup>Department of Anatomy, Medical School, <sup>2</sup>Department for Process Engineering, Faculty of Food Technology and Biotechnology, <sup>3</sup>Department of Engineering Mechanics, Faculty of Mechanical Engineering and Naval Architecture, Zagreb, Croatia, <sup>4</sup>Drug Discovery and Development, Genzyme, Framingham, United States

**P431-T EFFECT OF CATHEPSIN K INHIBITION ON BONE RESORPTION MARKERS IN HEALTHY POSTMENOPAUSAL WOMEN**

S. A. Stoch<sup>1</sup>, D. Miller<sup>1</sup>, K. van Dyck<sup>1</sup>, B. Jin<sup>1</sup>, D. Panebianco<sup>1</sup>, Q. Liu<sup>1</sup>, J. Stone<sup>1</sup>, K. M. Gottesdiener<sup>1</sup>, L. E. Wehren\*<sup>2</sup>, J. A. Wagner<sup>1</sup>  
<sup>1</sup>, <sup>2</sup>Medical Communications, Merck Research Laboratories, Rahway, United States

**P434-T EFFECTS OF CATHEPSIN K INHIBITORS ON BONE RESORPTION MARKERS IN ESTROGEN-DEFICIENT NON-HUMAN PRIMATES**

B. Pennypacker<sup>1</sup>, S. Adamski<sup>1</sup>, S. Rodan<sup>1</sup>, G. Rodan<sup>1</sup>, G. Wesolowski<sup>1</sup>, L. E. Wehren\*<sup>2</sup>, D. Kimmel<sup>1</sup>  
<sup>1</sup>Merck Research Laboratories, West Point, PA, <sup>2</sup>Medical Communications, Merck Research Laboratories, Rahway, United States

**P437-T EFFECTS OF TERIPARATIDE ON SERUM CALCIUM**

R. A. Wermers\*<sup>1</sup>, C. P. Recknor<sup>2</sup>, F. Cosman<sup>3</sup>, L. Xie<sup>4</sup>, E. V. Glass<sup>4</sup>, J. H. Krege<sup>4</sup>  
<sup>1</sup>Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, <sup>2</sup>Clinical Research, United Osteoporosis Centers, Gainesville, <sup>3</sup>Clinical Research Center, Helen Hayes Hospital, West Haverstraw, <sup>4</sup>Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, United States

**P440-T OSTEOPOROSIS SCREENING IN PATIENTS WITH PREVIOUS FRACTURES**

S. Ariogul\*<sup>1</sup>, B. B. Yavuz<sup>1</sup>, M. Halil<sup>1</sup>, Z. Ulger<sup>1</sup>, M. Cankurtaran<sup>1</sup>  
<sup>1</sup>Department of Internal Medicine, Division of Geriatric Medicine, Hacettepe University, Ankara, Turkey

**P445-T HIGH CA INTAKE PREVENTS DELETERIOUS EFFECTS OF REDUCED PROTEIN INTAKE ON SKELETAL GROWTH**

P. Ammann\*<sup>1</sup>, R. Rizzoli<sup>1</sup>  
<sup>1</sup>Division of Bone Diseases, Department of Rehabilitation and Geriatrics, Geneva, Switzerland

**P448-T THE PATTERN OF BONE DENSITY IN MEN 50-65 YEARS WITH HIP OR DISTAL RADIAL FRACTURES**

J. Åstrand\*<sup>1</sup>, M. Tägil<sup>2</sup>  
<sup>1</sup>Department of Orthopaedics, Lund University, Lund, Sweden, <sup>2</sup>,

**P451-T A BOUT OF RESISTANCE EXERCISE INCREASES SERUM OSTEOPROTEGERIN IN HEALTHY YOUNG MEN**

K. Brooke-Wavell\*<sup>1</sup>, S. F. Burns<sup>2</sup>, D. J. Stensel<sup>2</sup>  
<sup>1</sup>Human Sciences, <sup>2</sup>School of Sport and Exercise Sciences, Loughborough University, Loughborough, United Kingdom

**P454-T SOFT TISSUE BODY COMPOSITION AND HIP BONE MINERAL DENSITY IN HIP-FRACTURE**

## WOMEN

M. Di Monaco\*<sup>1</sup>, F. Vallero<sup>1</sup>, R. Tappero<sup>1</sup>, A. Cavanna<sup>1</sup>

<sup>1</sup>*Osteoporosis Research Center, Presidio Sanitario San Camillo, Torino, Italy*

### **P457-T THE EFFECTS OF 6 MONTHS GROWTH HORMONE SUPPLEMENTATION ON BIOCHEMICAL MARKERS OF BONE RESORPTION IN OSTEOPOROTIC WOMEN**

B. H. Durham\*<sup>1</sup>, F. Joseph<sup>2</sup>, A. Joshi<sup>2</sup>, H. D. White<sup>2</sup>, A. M. Ahmad<sup>2</sup>, J. P. Vora<sup>2</sup>, W. D. Fraser<sup>1</sup>

<sup>1</sup>*Clinical Chemistry and Metabolic Medicine, <sup>2</sup>Endocrinology, Royal Liverpool University Hospital, Liverpool, United Kingdom*

### **P460-T BONE MICROARCHITECTURAL CHANGES IN RHEUMATOID ARTHRITIS ASSESSED BY 3D MICRO-CT**

J. Garcia-Miguel\*<sup>1</sup>, A. Wright<sup>1</sup>, L. Pérez-Edo<sup>2</sup>, J. Blanch<sup>2</sup>, M. Mariñoso<sup>3</sup>, M. Círia<sup>2</sup>, D. Rotés<sup>2</sup>, J. Carbonell<sup>2</sup>, F. Wehrli<sup>1</sup>

<sup>1</sup>*Laboratory for Structural Research, University Hospital of Pennsylvania, Philadelphia, United States, <sup>2</sup>Department of Rheumatology, <sup>3</sup>Department of Pathology, Hospital del Mar de Barcelona (Autonomous University of Barcelona), Barcelona, Spain*

### **P463-T PIOGLITAZONE TREATMENT SIGNIFICANTLY DECREASED BONE MINERAL DENSITY IN A RANDOMISED PLACEBO-CONTROLLED STUDY IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME**

D. Glintborg\*<sup>1</sup>, M. Andersen<sup>1</sup>, C. Hagen<sup>1</sup>, A. Hermann<sup>1</sup>

<sup>1</sup>*Endocrinology, Odense University Hospital, Odense, Denmark*

### **P466-T PIOGLITAZONE INDUCES ADIPOCYTE DIFFERENTIATION IN A MURINE STROMAL CELL LINE, D1**

S. Hung\*<sup>1</sup>, L. Kang<sup>2</sup>, C. Chen<sup>3</sup>, C. Wang<sup>4</sup>, D. Chao<sup>1</sup>

<sup>1</sup>*Biological Sciences, National Sun Yat-Sen University, Kaohsiung, <sup>2</sup>Obstetrics and Gynecology, National Cheng Kung University Hospital, Tainan, <sup>3</sup>Orthopedic Surgery, <sup>4</sup>Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan*

### **P469-T EFFECT OF PREVALENT VERTEBRAL FRACTURES ON LIFE EXPECTANCY AND FUNCTIONAL PROGNOSIS AFTER HIP FRACTURES IN THE ELDERLY AGED 90 YEARS AND OLDER**

Y. Ishida\*<sup>1</sup>, T. Taguchi<sup>1</sup>

<sup>1</sup>*Department of Orthopaedic Surgery, Yamaguchi University Graduate School of Medicine, Ube-City, Japan*

### **P472-T CHANGES IN BONE TURNOVER MAKERS FOLLOWING GLUCOCORTICOID THERAPY FOR EXACERBATIONS OF INFLAMMATORY BOWEL DISEASE**

M. H. Kriel\*<sup>1</sup>, C. S. J. Probert<sup>1</sup>, W. D. Fraser<sup>2</sup>, J. H. Tobias<sup>1</sup>

<sup>1</sup>*Clinical Sciences at South Bristol, University of Bristol, Bristol, <sup>2</sup>Department of Clinical Chemistry, The University of Liverpool, Liverpool, United Kingdom*

### **P475-T EFFECTS OF ANABOLIC AND ANTI-CATABOLIC AGENTS ON MANDIBULAR BONE IN OVARECTOMIZED RATS**

A. Mavropoulos\*<sup>1</sup>, R. Rizzoli<sup>1</sup>, P. Ammann<sup>1</sup>

<sup>1</sup>*Division of Bone Diseases, Geneva University Hospitals, Geneva, Switzerland*

### **P478-T THE EFFICACY OF TERIPARATIDE (TPTD) IN REDUCING BACK PAIN IN PATIENTS AFFECTED BY SEVERE OSTEOPOROSIS WITH VERTEBRAL COMPRESSION FRACTURES (VCFS) AT THE EVOLUTION IN PSEUDOSTEOARTHRITIS**

A. Nardi\*<sup>1</sup>, L. Ventura<sup>2</sup>

<sup>1</sup>*SOS Dpt Patologia Osteoarticolare, Azienda ULSS 18, Rovigo, <sup>2</sup>Internal Medicine, Azienda Ospedaliera Carlo Poma, Mantova, Italy*

### **P481-T RELATION BETWEEN DIARY PRODUCTS AND TOTAL CALCIUM INTAKE IN A COHORT OF SPANISH POSTMENOPAUSAL WOMEN**

C. Carbonell\*<sup>1</sup>, X. Nogues<sup>2</sup>, I. Aymar<sup>2</sup>, M. Peña<sup>2</sup>, D. Grinberg<sup>3</sup>, S. Balcells<sup>3</sup>, L. Mellibovsky<sup>2</sup>, A. Supervia<sup>2</sup>, M. Checa<sup>4</sup>, L. Perez-Edo<sup>5</sup>, E. Caceres<sup>6</sup>, A. Diez-Perez<sup>2</sup>

<sup>1</sup>*Via Roma, ABS, <sup>2</sup>Internal Medicine, URFOA Hospital del Mar, <sup>3</sup>Genetics, Facultat de Biologia, Universitat Barcelona, <sup>4</sup>Obstetrics and Gynecology, <sup>5</sup>Rheumatology, <sup>6</sup>Traumatology and Orthopedics, URFOA Hospital del Mar, Barcelona, Spain*

- P484-T THE INCIDENCE OF SECONDARY HYPERPARATHYROIDISM AMONG POSTMENOPAUSAL WOMEN SUFFERING FROM END-STAGE KNEE OSTEOARTHRITIS. INTERMEDIATE RESULTS**  
K. A. Papavasiliou\*<sup>1</sup>, J. M. Kirkos<sup>1</sup>, M. E. Potoupnis<sup>1</sup>, I. K. Sarris<sup>1</sup>, F. E. Sayegh<sup>1</sup>, C. Dimitriou<sup>2</sup>, G. A. Kapetanios<sup>1</sup>  
<sup>1</sup>3<sup>rd</sup> Orthopaedic Department, Aristotle University of Thessaloniki Medical School, <sup>2</sup>Orthopaedic Department, "Hippokrateion" General Hospital, Thessaloniki, Greece
- P487-T RISK FACTORS FOR OSTEOPOROTIC FRACTURES IN BRAZILIAN MEN AND WOMEN – THE BRAZILIAN OSTEOPOROSIS STUDY (BRAZOS)**  
M. M. Pinheiro\*<sup>1</sup>, R. M. Ciconelli<sup>1</sup>, L. A. Martini<sup>2</sup>, M. B. Ferraz<sup>1</sup>  
<sup>1</sup>Rheumatology, Federal University of Sao Paulo, <sup>2</sup>Nutrition, Sao Paulo University, Sao Paulo, Brazil
- P490-T EVALUATION OF VALIDITY OF IOF'S ONE-MINUTE OSTEOPOROSIS RISK TEST FOR POSTMENOPAUSAL WOMEN**  
V. V. Povoroznjuk\*<sup>1</sup>, N. I. Dzerovich<sup>1</sup>, T. A. Karasevskaya<sup>1</sup>  
<sup>1</sup>Department of Clinical Physiology and Pathology of Locomotor Apparatus, Institute of Gerontology AMS of Ukraine, Kiev, Ukraine
- P493-T AROMATASE GENE POLYMORPHISMS ARE ASSOCIATED WITH HIP FRACTURE RISK**  
J. A. Riancho\*<sup>1</sup>, J. L. Perez-Castrillon<sup>2</sup>, J. del Pino<sup>3</sup>, F. Pinacho<sup>2</sup>, J. Gonzalez-Macias<sup>1</sup>, M. T. Zarrabeitia<sup>4</sup>  
<sup>1</sup>Internal Medicine, Hospital U M Valdecilla, University Cantabria, Santander, <sup>2</sup>Internal Medicine, Hospital U R Hortega, Valladolid, <sup>3</sup>Internal Medicine-Rheumatology, Hospital Universitario, Salamanca, <sup>4</sup>Legal Medicine, University Cantabria, Santander, Spain
- P496-T MENOPAUSE-RELATED CHANGES IN THE TRABECULAR TEXTURE OF THE VERTEBRAE, MEASURED BY HIGH RESOLUTION COMPUTED TOMOGRAPHY**  
E. J. A. Roldan\*<sup>1</sup>, R. Capiglioni<sup>2</sup>, V. Montangero<sup>3</sup>, F. Aude<sup>4</sup>, R. Luchini<sup>5</sup>  
<sup>1</sup>Scientific Direction, Gador S.A., Buenos Aires, <sup>2</sup>Inst. Tecnol Especiales, Univ. Abierta Interamericana, Rosario, <sup>3</sup>Osteology, Univ. Maimónides, Bs As, <sup>4</sup>Inst Tecnol Especiales, <sup>5</sup>Inst. Tecnol Especiales, Univ. Abierta Interamericana, Rosario, Argentina
- P499-T BONE MINERAL DENSITY, BONE TURNOVER MARKERS IN TYPE 1 DIABETIC WOMEN**  
A. P. Shepelekevich\*<sup>1</sup>, H. A. Kholodova<sup>2</sup>, J. V. Tolkachev<sup>3</sup>  
<sup>1</sup>Endocrinology, Belarusian State Medical University, Minsk, <sup>2</sup>, Belarusian Medical Postgraduate Academy, <sup>3</sup>, Republic Hospital of Medical Rehabilitation, Belarus
- P502-T DISCREPANCIES IN BONE MINERAL DENSITY AND FRACTURE RISK IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES – A META-ANALYSIS**  
P. Vestergaard\*<sup>1</sup>  
<sup>1</sup>The Osteoporosis Clinic, Aarhus Amtssygehus, Aarhus, Denmark
- P505-T A STATISTICAL ATLAS OF THE PROXIMAL FEMUR**  
O. M. Ahmad<sup>1</sup>, K. Engelke<sup>2</sup>, K. Ramamurthi<sup>3</sup>, K. E. Wilson\*<sup>3</sup>, R. H. Taylor<sup>1</sup>  
<sup>1</sup>Center for Computer-Integrated Surgical Systems and Technology, Johns Hopkins University, Baltimore, United States, <sup>2</sup>Institute of Medical Physics, University of Erlangen, Erlangen, Germany, <sup>3</sup>Skeletal Health, Hologic, Inc, Bedford, United States